In the QUSAR study, 80% of patients treated with guselkumab achieved a objective response.
New information presented during the 2022 American College of Gastroenterology (ACG) Annual Meeting successful Charlotte amusement guselkumab (TREMFYA) results successful an 80% objective effect complaint for patients with moderately to severely progressive ulcerative colitis.
The information travel from the QUSAR Induction survey and was presented by Bruce E. Sands, MD, MS, Chief of the Dr. Henry D. Janowitz Division of Gastroenterology astatine Mount Sinai Hospital, and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology) astatine the Icahn School of Medicine astatine Mount Sinai.
The survey included patients who were not achieving objective effect astatine week 12 who switched to subcutaneous guselkumab 200 mg.
In an interrogation with HCPLive®, Sand discussed the affirmative results and talked astir however determination are respective caller and breathtaking drugs soon to beryllium connected the marketplace that could alteration attraction for patients with inflammatory bowel illness (IBD).
Guselkumab is an interleukin-23 inhibitor, which is the aforesaid pathway arsenic risankizumab, a precocious approved attraction for patients with Crohn's disease.
Sands said the advent of IL-23 treatments could yet effect successful much personalized treatments for patients with IBD, but close present determination are much biomarkers for non-response than determination are for response.
“We’d emotion for the tract to determination to a precision medicine approach,” Sands said. “We’d emotion to spot that; we conscionable don’t person the markers yet.”
English (US)